Plateaus are normal physiology, not failure.
First, the reassurance: weight loss plateaus on GLP-1 medications are expected. They happen to essentially everyone. They do not mean the medication stopped working. They do not mean you need a higher dose. And they usually do not mean you're doing something wrong.
Here's what's actually going on.
When you lose weight, your body adapts. Resting metabolic rate decreases — because you're carrying less mass, and because the body has compensatory mechanisms that try to resist weight loss (this is well-documented and sometimes called metabolic adaptation or adaptive thermogenesis). Simultaneously, appetite-regulating hormones shift to encourage eating. Leptin drops. Ghrelin may increase. The energy equation that produced your initial weight loss has changed because your body has changed.
The GLP-1 medication is still working. It's still suppressing appetite, slowing gastric emptying, and altering glucose metabolism. But the caloric deficit it created at your higher weight may no longer exist at your current weight. Your body has closed the gap.
What I evaluate when a patient plateaus.
When a patient tells me their weight loss has stalled, I don't immediately reach for the dose adjustment button. I work through a diagnostic hierarchy, because the right response depends on the cause.
Is it actually a plateau?
Three weeks of stable weight is not a plateau. It's normal variation. Weight fluctuates daily based on hydration, sodium intake, menstrual cycle, bowel habits, GI side effects, and stress. I look at the trend over 4-6 weeks before concluding that weight loss has truly stalled. This is one reason I use smart scale data — I can see the daily readings and the moving average. Sometimes the patient thinks they've plateaued, but the trend line is still moving slowly downward.
Medication adherence
Before investigating further, I confirm consistent adherence. Missed doses, injection technique issues, or irregular timing can all blunt the medication's effect. This is a straightforward conversation, not an accusation.
Has caloric intake changed?
One of the most common reasons for a true plateau is that the appetite suppression has moderated. Early in treatment, the appetite effect is profound — many patients report dramatically reduced food interest. Over time, the body partially adapts to the medication. Patients start eating slightly more without realizing it. Not bingeing. Not "cheating." Just gradually returning toward a higher caloric intake because the medication's grip on appetite has softened.
I don't judge this. It's expected physiology. But it's worth identifying, because the intervention might be dietary strategy rather than dose escalation.
Protein and dietary pattern
Calorie quantity matters, but so does composition. A patient who's eating 1,400 calories a day but only getting 50 grams of protein is in a very different metabolic position than one eating 1,400 calories with 120 grams of protein. Low protein intake accelerates muscle loss, which lowers metabolic rate, which closes the caloric gap faster. Sometimes the plateau breaks when we fix the macronutrient composition rather than reducing total calories further.
Physical activity
Has exercise intensity or frequency decreased? Has the patient been sedentary due to illness, travel, or schedule changes? Resistance training in particular supports metabolic rate during weight loss. A lapse in activity can contribute to a stall.
Sleep
Poor sleep quality or insufficient sleep duration is associated with increased hunger hormones, reduced insulin sensitivity, and impaired fat oxidation. If sleep has deteriorated, it's worth addressing as a contributing factor.
GI side effects and fluid variation
Nausea, constipation, or reduced fluid intake can cause weight fluctuations that look like a plateau. Constipation in particular can mask ongoing fat loss. Sometimes resolving GI issues reveals that weight loss was continuing all along.
Dose and duration
Has the patient been on the current dose long enough for it to take full effect? Is there room to titrate? These are considerations before pursuing a workup.
Other medications that promote weight gain
Certain antidepressants, beta-blockers, insulin, corticosteroids, and other medications can work against GLP-1 therapy. A medication review is part of the workup.
Targeted medical evaluation when symptoms suggest it
When history or symptoms suggest an underlying condition — such as new fatigue, cold intolerance, or other changes beyond the plateau itself — targeted evaluation for thyroid dysfunction, hormonal changes, or metabolic factors may be warranted.
- Thyroid function. If a patient develops fatigue, cold intolerance, or constipation beyond what the medication explains, checking TSH and free T4 is appropriate. Hypothyroidism can emerge during weight loss or may have been subclinical before treatment.
- Insulin resistance. In patients with known significant insulin resistance or early type 2 diabetes, the metabolic response to weight loss may be blunted. Sometimes adding metformin or adjusting the GLP-1 medication helps.
- Hormones. In men with symptoms of low testosterone (fatigue, reduced libido, muscle loss beyond expected), or women with perimenopausal symptoms affecting sleep and metabolism, hormonal evaluation may clarify the picture.
- Adrenal disorders. These should be evaluated when clinically suspected based on specific signs and symptoms.
Illustrative example: An unexpected plateau accompanied by fatigue, cold intolerance, or constipation may justify checking thyroid function. If subclinical hypothyroidism is identified, addressing it can be part of the solution. The point is that the plateau wasn't a GLP-1 problem — it was an unrelated metabolic issue that nobody found because nobody was looking beyond the prescription.
When a dose increase is the right move.
Sometimes it is. If a patient has genuinely plateaued, the basics are covered (adequate protein, resistance training, caloric intake is reasonable), there's no underlying metabolic issue, and they haven't yet reached the maximum therapeutic dose — then increasing the dose is a legitimate next step. The medication may need a stronger signal at the receptor level to maintain the caloric deficit.
But "increase the dose" should be a considered decision, not the default response to any pause in weight loss. The higher the dose, the more likely you are to encounter GI side effects, and there's a point of diminishing returns where the side effects outweigh the incremental benefit.
When switching medications makes sense.
If a patient has titrated to the maximum semaglutide dose and has truly plateaued with all other factors addressed, switching to tirzepatide is worth discussing. The dual GLP-1/GIP mechanism may provide additional weight loss in patients who have plateaued on a GLP-1 agonist alone. This isn't guaranteed — but it's a reasonable clinical strategy when the current medication has been fully optimized.
When the plateau is the new baseline.
Sometimes the plateau is your new set point — at least for now.
The body has powerful homeostatic mechanisms that defend against weight loss. At some point, those mechanisms may reach an equilibrium with the medication. You may not reach the weight you had in mind. That doesn't mean the treatment failed. If you started at 260 and you're at 215 and the scale won't budge — you've lost 45 pounds. Your cardiovascular risk is meaningfully lower. Your metabolic profile is improved. Your body composition is better. The fact that you wanted to reach 195 doesn't erase the clinical significance of what you've achieved.
My job is to help you get as far as your body will safely go — not to chase an arbitrary number at the expense of muscle mass, metabolic health, or quality of life.
And if the scale does stall, we shift the focus: body composition, strength, metabolic markers, how your clothes fit, how you feel. Weight is one metric. It's not the only one, and it's often not the most important one.